Please note that following on from information provided to NICE by the company in February 2018, the appraisal of Biotin for treating primary and secondary progressive multiple sclerosis [ID919] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 919

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Medday Pharmaceuticals
Others Department of Health
  NHS East Riding of Yorkshire CCG
  NHS England
  NHS Haringey CCG
  Welsh Government
Patient carer groups Brain and Spine Foundation
  The Brain Charity
  Disability Rights UK
  Leonard Cheshire Disability
  MS-UK
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Geriatrics Society
  British Neuropathological Society
  Institute of Neurology
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Roche (ocrelizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research Trust
  British Neurological Research Trust
  Cochrane Multiple Sclerosis Group
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in February 2018, the appraisal of Biotin for treating primary and secondary progressive multiple sclerosis [ID919] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
16 February 2018 Suspended. The company have notified the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that it wishes to withdraw its application for a marketing authorisation for biotin (Qizenday), for the treatment of progressive multiple sclerosis. This appraisal will therefore now be suspended.
01 November 2017 Invitation to participate
01 September 2016 Draft scope documents
22 July 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual